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Abstract
We have previously shown that injury-induced neointima formation was rescued by adenoviral-Nogo-B gene
delivery. Integrase-competent lentiviral vectors (ICLV) are efficient at gene delivery to vascular cells but present
a risk of insertional mutagenesis. Conversely, integrase-deficient lentiviral vectors (IDLV) offer additional
benefits through reduced mutagenesis risk, but this has not been evaluated in the context of vascular gene
transfer. Here, we have investigated the performance and genetic safety of both counterparts in primary human
vascular smooth muscle cells (VSMC) and compared gene transfer efficiency and assessed the genotoxic po-
tential of ICLVs and IDLVs based on their integration frequency and insertional profile in the human genome.
Expression of enhanced green fluorescent protein (eGFP) mediated by IDLVs (IDLV-eGFP) demonstrated effi-
cient transgene expression in VSMCs. IDLV gene transfer of Nogo-B mediated efficient overexpression of Nogo-
B in VSMCs, leading to phenotypic effects on VSMC migration and proliferation, similar to its ICLV version and
unlike its eGFP control and uninfected VSMCs. Large-scale integration site analyses in VSMCs indicated that
IDLV-mediated gene transfer gave rise to a very low frequency of genomic integration compared to ICLVs,
revealing a close-to-random genomic distribution in VSMCs. This study demonstrates for the first time the
potential of IDLVs for safe and efficient vascular gene transfer.
Introduction
Vascular gene delivery strategies have been exten-sively explored in the context of prevention of neointima
formation (NIF) (Rissanen and Yla-Herttuala, 2007; Karvinen
and Yla-Herttuala, 2010; Hedman et al., 2011). There is a re-
quirement to identify and provide a safe and effective gene
transfer strategy for therapeutic gene delivery to attenuate the
NIF in this clinical setting. There are many therapeutic genes
that have been reported to modulate vascular smooth muscle
cell (VSMC) migration and/or proliferation and successfully
prevent in-stent restenosis (ISR) and/or vein graft failure in
animal models. These include endothelial nitric oxide syn-
thase (eNOS) ( Janssens et al., 1998; Varenne et al., 1998); in-
ducible nitric oxide synthase (iNOS) (Kibbe et al., 2001); tissue
inhibitors of Metalloproteinases 1-3 (TIMPs 1-3) (George et al.,
1998a; George et al., 1998b; George et al., 2000; George et al.,
2011); p53 (George et al., 2001); and Nogo-B (Acevedo et al.,
2004; Kritz et al., 2008). The majority of studies have used
adenovirus-mediated gene transfer due to its relative ease of
production. Indeed, advances have demonstrated stent-based
adenoviral delivery of TIMP-3 ( Johnson et al., 2005), and eNOS
(Sharif et al., 2008) reduced ISR in vivo. However, the com-
monly used serotype 5 vectors (Ad5) display a high frequency
of neutralizing antibodies in the general population (Abbink
et al., 2007; Parker et al., 2009) and relatively poor levels of gene
transfer to VSMC, the target cell type of many of the afore-
mentioned strategies. Lack of coxsackie and adenovirus re-
ceptor (CAR) on this cell type is purported to be the main
reason for low level VSMC gene transfer (Nicklin et al., 2001).
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Nogo (RTN4)-spliced variants A, B, and C are members
of the reticulon superfamily of transmembrane proteins as-
sociated primarily with the endoplasmic reticulon (ER)
(Oertle and Schwab, 2003; Teng and Tang, 2008). Nogo-B has
many biological roles; for example, it acts as a pro-apoptotic
protein/tumor suppressor (Tagami et al., 2000; Li et al., 2001;
Oertle et al., 2003; Watari and Yutsudo 2003; Tambe et al.,
2004; Kuang et al., 2006); plays a role in the acute inflam-
mation response (Di Lorenzo et al., 2010) and in pulmonary
hypertension (Munoz and Zorzano 2011; Sutendra et al.,
2011); is a regulator in vascular (Acevedo et al., 2004), renal
(Marin et al., 2010) and hepatic (Zhang et al., 2011) injuries;
and plays roles in inflammation of the asthmatic lung
(Wright et al., 2010; Xu et al., 2011) and inflammation and
tissue repair in response to ischemia (Yu et al., 2009). Pre-
vious studies have documented high levels of Nogo-B in
vascular endothelial cells (VECs), VSMCs (Acevedo et al.,
2004) and monocytes/macrophages (Paszkowiak et al., 2007;
Rodriguez-Feo et al., 2007; Yu et al., 2009).
Endogenous Nogo-B expression is important for vascular
maintenance and remodeling (Acevedo et al., 2004), as well
as cardiac function (Bullard et al., 2008). Indeed, mice defi-
cient in Nogo-A/B demonstrated accelerated rates of NIF
after acute vascular injury, which were attenuated/rescued
by adenoviral gene transfer of Nogo-B (Acevedo et al., 2004).
Nogo-B expression is down-regulated in human arterial
atherosclerotic plaques (Rodriguez-Feo et al., 2007; Lee et al.,
2009), stenotic lesions (Rodriguez-Feo et al., 2007), and le-
sions of aortic aneurysms (Pan et al., 2007), and therefore
can be regarded as a biomarker for injury-induced NIF
(Paszkowiak et al., 2007). Hence, Nogo-B is a therapeutic
candidate gene in the vascular gene therapy setting for the
prevention of the NIF following acute vascular injury.
Nogo-B acts as a positive and negative regulator of vascular
cells by mediating the chemo-attraction of VECs (Acevedo
et al., 2004; Miao et al., 2006; Zhao et al., 2010) and antago-
nizing the migration (Acevedo et al., 2004; Kritz et al., 2008)
and proliferation (Kritz et al., 2008) of VSMCs, respectively.
We have previously shown that NIF was rescued in a porcine
vein graft model and a wire injured mouse model by adeno-
viral gene transfer of Nogo-B (Kritz et al., 2008).
In comparison to Ad5-based systems, there are many ad-
vantageous characteristics that suggest lentiviral vectors
(LV) to be favorable gene delivery vectors for vascular gene
transfer. LVs are highly efficient at transducing vascular cells
(Dishart et al., 2003; Cefai et al., 2005; Qian et al., 2006; Yang
et al., 2010) and have been considered as a useful vector for
delivering therapeutic interventions to reduce NIF following
acute vascular injury in vivo (Qian et al., 2006; Yang et al.,
2010). LVs are integration-competent (ICLV) and integrate a
transgene copy into the chromosome of the target cell, which
allows for efficient, stable, and long-term transgene expres-
sion (Matrai et al., 2010).
In contrast, integration-deficient lentiviral vectors (IDLV)
are very attractive gene transfer tools since they maintain the
efficiency of gene transfer yet have a reduced frequency of
integration (Yanez-Munoz et al., 2006; Wanisch and Yanez-
Munoz, 2009). IDLVs mediate transient gene expression in
proliferating cells (Nightingale et al., 2006; Philippe et al.,
2006; Apolonia et al., 2007; Matrai et al., 2011) and provide
stable and efficient transgene expression in nondividing cells
(Philippe et al., 2006; Yanez-Munoz et al., 2006; Apolonia
et al., 2007; Rahim et al., 2009; Matrai et al., 2011), with
minimal integration frequencies (Yanez-Munoz et al., 2006;
Apolonia et al., 2007; Wanisch and Yanez-Munoz 2009;
Matrai et al., 2011) associated with a reduced risk of inser-
tional mutagenesis or oncogenesis (Hacein-Bey-Abina et al.,
2003a; Hacein-Bey-Abina et al., 2003b; Hacein-Bey-Abina
et al., 2008; Howe et al., 2008; Kane et al., 2010).
Additionally, IDLVs offer an alternative yet promising
option that would be highly advantageous in vascular cell
gene transfer (George et al., 2006; White et al., 2007) associ-
ated with a higher safety profile. Large-scale studies denot-
ing the integration pattern and genotoxicity of LVs have
shown a substantially reduced frequency of insertional in-
duced alteration of cellular genes compared to gamma-
retroviral vectors (Montini et al., 2006; Modlich et al., 2009;
Montini et al., 2009; Balaggan et al., 2011). However, an in-
herent genotoxic risk based on vector design is still present
(Nowrouzi et al., 2011). In particular, the interaction of the
LV integration machinery with cellular factors may be re-
sponsible for the proposed cell type- and species-specific
integration pattern of LV-based vectors (Lewinski et al., 2006;
Bartholomae et al., 2011; Biasco et al., 2011; Biasco et al., 2012).
Integration-site (IS) analyses of the first clinical trial for
treatment of adrenoleukodystrophy (ALD) with LV-based
vectors has not revealed any insertional-induced side effects
(Cartier et al., 2009). A comparative analysis of IS hotspots has
demonstrated a mega base-wide LV integration preference
without obvious skewing of oncogene targeting (Biffi et al.,
2011). To date, large-scale studies of LV integration patterns
were performed in cell lines and primary murine and human
cells of the hematopoietic system (Bushman et al., 2005;
Nowrouzi et al., 2011). Due to an inserted mutation in the LV
integrase gene, the integration of IDLV-based vectors is not
driven by the viral integrase but by transient DNA-double
strand (DSB) sites in the host genome, with residual integrase
activity leading to lower frequency of random integration
frequency as compared to ICLVs (Yanez-Munoz et al., 2006;
Wanisch and Yanez-Munoz 2009; Matrai et al., 2011). How-
ever, insertional mutagenesis remains a risk, even with such a
rare integrating vector system; therefore, comprehensive ge-
nome-wide analysis of integration frequency and pattern of
integrating and rare integrating vector systems in the target
cell-type remains a requirement. The frequency of IDLV vec-
tors to integrate as well as the integration pattern of ICLV
vectors in human VSMCs is current unknown. This study
addresses whether IDLV gene transfer of Nogo-B can mediate
overexpression in VSMCs to induce phenotypic effects asso-
ciated with a reduced risk of genotoxicity.
Materials and Methods
Materials
Human saphenous vein segments were obtained from pa-
tients, who gave informed consent, undergoing coronary ar-
tery bypass grafting. Ethical permissionwas obtained from the
West Glasgow Ethics Committee (reference number: 06/
S0703/110). Reagents were purchased from Sigma-Aldrich
(Poole, United Kingdom) and tissue culture reagents from
Gibco (Invitrogen, Paisley, United Kingdom), unless other-
wise stated. All primers and probes (oligonucleotides) were
obtained fromMWG-Biotech (Ederberg, Germany). Nuclease-
free water (not diethyl pyrocarbonate–treated) was purchased
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from Ambion (Applied-Biosystems/Ambion, Warrington,
United Kingdom).
Plasmids
We used the lentiviral construct plasmid encoding the
marker gene, enhanced green fluorescent protein (eGFP),
(pHR’SIN-cPPT-SFFV-eGFP-WPRE) under the control of the
spleen focus forming virus (SFFV) promoter, as published
previously (Demaison et al., 2002). Nogo-B complementary
DNA (haemagglutinin tagged) (Acevedo et al., 2004) was
cloned into the lentiviral construct plasmid containing a
multiple cloning site (MCS) (pHR’SIN-cPPT-SFFV-MCS-
WPRE) (Ward et al., 2011) using BamHI andXhoI sites. All LVs
were pseudotyped with the vesicular stomatitis virus glyco-
protein (VSV-g) expressed by the pMD.G2 plasmid, as previ-
ously described (Demaison et al., 2002). The second-
generation LV packaging plasmid containing either the wild-
type integrase gene (pCMV delta R8.74) or integrase-deficient
gene (pCMV delta R8.74 D64V) was used, as detailed else-
where (Yanez-Munoz et al., 2006).
Lentiviral production and titre assay
Self-inactivating (SIN) HIV-1–based LVs were produced
using a three-plasmid transient transfection system and
concentrated by ultracentrifugation at 90353 · g (23,000 rpm)
for 1 hr and 7min at 4C using a Beckmann ultracentrifuge,
as previously described (Demaison et al., 2002; Buckley et al.,
2008). LV stocks were titrated by infecting 293T cells (ATCC-
LGC Standards, Middlesex, United Kingdom) with serial
dilutions of LVs (Demaison et al., 2002). We quantified LV
genomic copy number in DNA extracted from 293T cells,
3 days post-infection, by TaqMan quantitative polymerase
chain reaction (PCR), as previously described, according to a
published protocol for late reverse transcriptase amplicon
quantification (Butler et al., 2001), and standard curves were
generated using LV construct plasmid DNA as described
(Butler et al., 2001). LV titres were calculated as infectious
viral units per ml (iu/ml).
SMC isolation, SMC culturing,
and lentiviral transduction
VSMCs were isolated from human saphenous vein seg-
ments using the explant technique (Southgate and Newby,
1990) and cultured in smooth muscle cell (SMC) growth media
2 (PromoCell, Heidelberg, Germany) with the addition of the
supplement mix, plus 10% (v/v) fetal calf serum (FCS) (for a
15% (v/v) FCS final concentration), 1% (v/v) penicillin,
100lg/ml streptomycin, and 2mM L-glutamine (15% com-
plete SMC media). Passages 3–8 were used for experiments.
Ad5-expressing haemagglutinin (HA)-tagged full-length hu-
man Nogo-B (Ad-Nogo-B) was generated as previously de-
scribed (Acevedo et al., 2004; Kritz et al., 2008) and Ad5
expressing eGFP (Ad-eGFP) was obtained from Crucell (Cru-
cell, TheNetherlands). Amultiplicity of infection (MOI) per cell
of LVorAdwas calculated on the basis of infective titres, iu/ml
for LVs and plaque forming units per ml (pfu/ml) for Ad, and
an accurate cell count before infection. Equivalent ‘‘amounts’’
were used for ICLVs and IDLVs in relation to their TaqMan
quantitative PCR titres. Cells were infected with viral vectors
for 18hr in complete SMC media, subsequently washed twice
in phosphate buffered saline (PBS), and maintained in com-
plete SMC media. LV transductions were performed in the
presence of 8lg/ml of polybrene.
Fluorimetry and bicinchoninic acid assay
Expression of eGFP was visualized by fluorescence mi-
croscopy prior to cell lysis using 0.2% (v/v) Triton-X-100
PBS. The expression of eGFP was quantified by plate assay
(fluorimetry) using a Wallac Victor 2 and recombinant eGFP
(Clontech, Basingstoke, United Kingdom) as a standard, as
previously described (Dishart et al., 2003). Expression of
eGFP was normalized to total mg of protein present (deter-
mined by a bicinchoninic acid [BCA] assay [Fisher Scientific,
Loughborough, United Kingdom]), and results were ex-
pressed as relative fluorescent units (RFU)/mg protein
(Dishart et al., 2003).
Immunocytofluorescence
Nogo-B immunocytofluorescence in VSMCs was per-
formed 5 days post-infection as described previously
(Acevedo et al., 2004; Rodriguez-Feo et al., 2007; Kritz et al.,
2008; Yu et al., 2009). Briefly, VSMCs were fixed in 4%
paraformaldehyde (PFA) for 10min, permeabilized for
10min in 0.1% (v/v) Triton X-100 in PBS, blocked using 10%
(v/v) donkey serum and 1% (w/v) BSA in PBS for 30min,
and incubated with 2 lg/ml of goat anti-human Nogo (N-18)
immunoglobulin G (IgG) or isotype-matched goat IgG con-
trol in PBS containing 10% donkey serum and 1% (w/v) BSA
for 18 hr at 4C. Nogo-B staining was visualized using 4lg/
ml of Alexa-Fluor 555 donkey anti-goat IgG (Invitrogen) and
mounted with Prolong-Gold anti-fade reagent with 4’,6-
diamidino-2-phenylindole (DAPI; Invitrogen). Micrographs
were captured using a Carl Zeiss LSM 510 Meta confocal
microscope at · 630 magnification, and images were digi-
tized under constant exposure time, gain, and offset.
Migration assay
VSMC migration was assessed by a scratch-wound–
mediated cell migration assay (Liang et al., 2007). Briefly,
VSMCs were seeded for 50 to 60% confluence into 8-well
culture slides (BD Biosciences, Oxford, United Kingdom) for
16 to 18 hr prior to LV infection. Once VSMCs reached 100%
confluence, a scratch was created using a sterile p200 pipette
tip. VSMCs were washed twice in PBS to remove cell debris
and to smooth the edge of the scratch. VSMCs were main-
tained in 15% complete SMC media and in the incubator at
37C. Reference lines close to the edge of the scratch were
marked and images of the scratch acquired at 0 hours and 10
hours using bright-field microscopy. After 10 hours post-
wounding, VSMCs were fixed in 4% PFA and haematoxylin
stained and mounted in DPX. Absolute migration was
measured (lm) as farthest distance the VSMCs migrated
from the wound edge (average of 10 migration distances of
three independent microscope fields for each condition in
triplicate) using Image Pro-Plus software (Media Cyber-
netics, Bethesda, Maryland).
Proliferation and apoptosis assays
For both assays, VSMCs were seeded for 30% confluence
after 16 to 18 hr incubation and VSMC quiescence was
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induced with serum-free media [MEM supplemented with 1%
(v/v) penicillin, 100lg/ml streptomycin, 2mM L-glutamine,
and 1mM sodium pyruvate (Sigma-Aldrich)] for 48 hr prior
to LV infection with 15% complete SMC media. Proliferation
was assessed using a CellTiter 96 Non-Radioactive Cell
Proliferation (MTT) assay (Promega, Southampton, United
Kingdom) according to manufacturer’s instructions and op-
tical density quantified using a Wallac Victor 2 at wave-
length of 570 nm (Kritz et al., 2008). Apoptosis was assessed
using Caspase-Glo 3/7 assay (Promega) according to the
manufacturer’s instructions and luminescence quantified
using a Wallac Victor 2. Caspase 3/7 activities for all samples
were normalized to that of an equal protein amount, and
the results were expressed as relative luminescence units
(RLU)/mg protein.
Integration site analysis
Linear amplification-mediated (LAM)-PCR insertion site
analyses, 454 pyrosequencing and bioinformatical datamin-
ing. 5’long terminal repeat (LTR)- and 3’LTR-mediated
LAM-PCR analyses were performed as previously described
(Schmidt et al., 2007; Paruzynski et al., 2010). In brief, linear
PCR was performed on 1lg of DNA from ICLV- and IDLV-
transduced smooth muscle cells. After magnetic capture of
the biotinylated single-stranded linear PCR products second-
strand DNA synthesis was performed. The resulting double-
stranded fragments were digested with Tsp509I or MseI
respectively, and after ligation of a linker cassette the LAM-
PCR amplicons were amplified by two exponential PCR
steps. The resulting LAM-PCR amplicons were further pre-
pared for 454 pyrosequencing (GS Flx; Roche Diagnostics,
Basel) as described previously (Paruzynski et al., 2010). Raw
LAM-PCR amplicon sequences were separated according to
the introduced barcode, trimmed further, and aligned to the
human genome sequence using BLAT (bioinformatics) (as-
sembly February 2009) (Kent, 2002; Paruzynski et al., 2010).
The propensity of IS-forming common insertion sites (CIS)
was analyzed based on previously published mathematical
methods (Suzuki et al., 2002; Abel et al., 2007; Abel et al.,
2011) modified based on a new statistical comparison with a
generated random data set equivalent to the actual numbers
of retrieved IS (Fronza et al., manuscript in preparation).
Briefly, to each CIS is associated a probability value that
reduce the number of false positive calls resulting from in-
creasing numbers of total IS in the genome.
Q-PCR for vector copy number. Vector copy number
estimation was performed as described previously (Par-
uzynski et al., 2012) with modifications for calculating the
relative quantification of vector copies per genome. Briefly,
vector copies were amplified with LTR specific primers
(SKLTR 3: AGCTTGCCTTGAGTGCTTCA; LV 2 rev:
GAGTCCTGCGTCGAGAGAGC) and cell copy numbers by
hEPO specific primers (hEpoR-fw: CTGCTGCCAGCTTT
GAGTACAC; hEpoR-rev: GAGATGCCAGAGTCAGATA
CCAC ). Q-PCR was performed on the LightCycler LC480
system using the SYBRGREEN I Mix (Roche) with 30 ng of
genomic DNA from ICLV- and IDLV-transduced samples 14
days post transduction. For calculating vector copy numbers
relative to genome copies, the LightCycler LC480 Software
(Roche) was used, and values from the ICLV- and IDLV-
transduced samples were normalized to a reference DNA
obtained from a HeLa single-cell clone (D10) harboring one
vector copy per genome.
Statistical analysis. All values are expressed as the
mean – SEM of triplicates and three independent experiments
were performed (representative of each other). Data were
tested for, and shown to exhibit, Gaussian distribution by
applying the Shapiro-Wilk normality test to the data. Results
were statistically analyzed using the student’s unpaired t-test
or one-way ANOVA for Bonferroni’s multiple comparisons.
Statistical significance was assigned when p< 0.05 (GraphPad
Prism v4, La Jolla, California).
Results
IDLV-mediated gene transfer in human VSMCs
We first assessed the transduction efficiency mediated by
IDLVs (IDLV-eGFP) versus their integrase-competent coun-
terparts (ICLV-eGFP) at increasing MOIs of 5, 10, 25, and 50
in VSMCs. Expression of eGFP in VSMCs at 3, 7, and 14 days
post-infection were visualized by fluorescence microscopy,
prior to VSMC lysates, and quantified for eGFP expression
by fluorimetry (normalized to protein). IDLV-eGFP facili-
tated efficient transgene expression in VSMCs, parallel to its
integration-competent version (Fig. 1A). As expected, during
cell division, transgene expression profiles of IDLVs decreased
in a time-dependent manner from 3 days to 14 days post
infection at all MOIs and mediates a bit less transgene ex-
pression than ICLV counterparts at all MOIs (Fig. 1A). Re-
presentative micrographs illustrated efficient eGFP expression
in VSMCs mediated by IDLVs 3 and 7 days post infection at
an MOI of 50 (Fig. 1 B). Immunocytofluorescence staining for
Nogo-B indicated that both ICLV-Nogo-B and IDLV-Nogo-B
mediated efficient overexpression of Nogo-B in VSMCs 5 days
post-infection at an MOI of 50, compared to their eGFP con-
figurations and endogenous Nogo-B levels observed in un-
infected VSMCs (Fig. 1C). Collectively, these data support the
notion that IDLVs mediate efficient gene transfer to primary
human VSMCs, provide robust induction of transgene ex-
pression, and transgene expression was lost over time.
Effect of IDLV-Nogo-B on human VSMC migration
Previous reports have demonstrated that the N-terminus of
Nogo-B mediates a dose-dependent inhibition of VSMC mi-
gration induced by platelet-derived growth factor-BB (PDGF-
BB) (Acevedo et al., 2004). We have previously shown that
adenoviral overexpression of Nogo-B reduced PDGF-BB–
induced migration rate of VSMCs (Kritz et al., 2008). We
therefore examined the effect of Nogo-B overexpression me-
diated by IDLV-Nogo-B on VSMC phenotypes. Migration
was assessed using a scratch-wound–mediated cell migration
assay and quantified 3 days post infection. A significant re-
duction in VSMCmigration was observed after infection with
IDLV-Nogo-B, compared to IDLV-eGFP, at both MOIs of 25
and 50 and uninfectedVSMCs (MOI of 25: 106.24– 7.87 lmvs.
174.16 – 6.49 lm [39% significant reduction in VSMC migra-
tion] or 170.15– 8.04 lm [38%], p < 0.001, respectively, and
MOI of 50: 125.98– 8.66 lm vs. 178.9– 8.78 lm [30%] or
170.15 – 8.04 lm (26%), p < 0.001 or p < 0.01, respectively) (Fig.
2A). Micrographs also illustrated IDLV-Nogo-B transduction
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in VSMCs inhibited migration, compared with IDLV-eGFP
and untransduced VSMCs (Fig. 2B). Interestingly, our results
also indicated IDLV-Nogo-B was as efficient as ICLV-Nogo-B
in mediating a reduction in VSMC migration (Fig. 2A and B).
Therefore, IDLV-mediated overexpression of Nogo-B attenu-
ates VSMCmigration. To note, the differences between VSMC
migration at MOIs of 25 and 50 were not different in this
scratch migration assay due to the sensitivity of this assay not
depicting differences precisely.
IDLV-Nogo-B-mediated human VSMC proliferation
Overexpression of Nogo-B negatively regulates VSMC
proliferation in response to serum and PDGF-BB stimulation,
as indicated by previous studies using adenovirus-based
strategies (Kritz et al., 2008). We therefore investigated the
effect of IDLV-Nogo-B on VSMC proliferation. IDLV-Nogo-B
significantly reduced VSMC proliferation following 5 days
post infection at MOIs of 25 and 50, compared to IDLV-eGFP
FIG. 2. IDLV-Nogo-B re-
duced VSMC migration. (A)
IDLV-Nogo-B reduced VSMC
migration, as indicated with a
scratch-wound–stimulated mi-
gration ofVSMCs at 3 dayspost
infection. *p<0.01 vs. unin-
fected, #p<0.001 vs. their LV-
eGFP control or uninfected. (B)
Representative micrographs.
Scale bar, 100lm.
FIG. 1. IDLV-mediated gene
transfer in VSMCs. (A–B)
IDLVs mediated efficient eGFP
expression in VSMCs. (A)
*p<0.01, #p<0.001 vs. IDLV-
eGFP. (B) Representative mi-
crographs at an MOI of 50.
Scale bar, 100lm. (C) IDLV-
Nogo-B (at MOI of 50) facili-
tatedNogo-Boverexpression in
VSMCs (5 days post-infection)
as verified by immunocyto-
fluorescence. IDLV, integrase-
deficient lentiviral vectors;
VSMC, vascular smooth mus-
cle cells; eGFP, enhanced green
fluorescent protein; MOI, mul-
tiplicity of infection. Color
images available online at
www.liebertpub.com/hum
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control and uninfected VSMCs (MOI 25: 0.14 – 0.0084 optical
density [OD] at 570 nm vs. 0.29 – 0.01 OD [52% significant
reduction in VSMC proliferation] or 0.33– 0.0038 OD [58%],
p < 0.001, respectively, and MOI 50: 0.074 – 0.0011 OD vs.
0.2 – 0.013 OD (63%) or 0.35 – 0.015 OD [79%], p < 0.001, re-
spectively) (Fig. 3A). Representative images are also shown
at MOI of 50 (Fig. 3B). In addition, these data also demon-
strated that IDLV-Nogo-B was as effective as ICLV-Nogo-B
in reducing VSMC proliferation (Fig. 3A).
Previous reports have implicated that overexpression of
Nogo-B can act as a pro-apoptotic protein in various cancer
cells (Li et al., 2001; Tambe et al., 2004; Kuang et al., 2006).
However, we have previously reported that the over-
expression of Nogo-B facilitated by adenoviral vectors in the
vasculature did not induce apoptosis (Kritz et al., 2008). We
therefore assessed the induction of apoptosis mediated by
LVs overexpressing Nogo-B in VSMCs. VSMC apoptosis
was determined by a caspase-3/7 activity assay 5 days
post-transduction. Results indicated that IDLV-Nogo-B and
ICLV-Nogo-B at an MOI of 50 did not significantly induce
casapse-3/7 activation (Fig. 3C). Therefore, IDLV-mediated
elevation in Nogo-B blocks VSMC proliferation and migra-
tion in the absence of an effect on VSMC apoptosis.
Lentiviral integration site selection in human VSMCs
The above data suggests that IDLVs are effective in the
context of VSMC gene transfer. Vector safety in the clinical
setting is a major factor in the advancement of genetic ther-
apies. To ascertain whether an improved safety profile of
IDLV compared to ICLV could be observed in the context of
vascular gene transfer, we next performed large-scale IS
analyses of ICLV and IDLV vectors following infection of
primary human VSMCs, and harvested DNA at 14 days
post-transduction. We assessed integration by LAM-PCR
and 454 pyrosequencing (Schmidt et al., 2007; Gabriel et al.,
2009; Paruzynski et al., 2010).
ICLV and IDLV vectors were used to transduce three in-
dependent humanVSMC batches isolated from three different
individuals at MOIs of 10, 25, and 50. Subsequent sequencing
of LAM-PCR amplicons resulted in the identification of 10,752
unique ICLV IS and 1,086 multiple mappable IS sequences,
mainly due to location in repetitive elements of the human
FIG. 3. IDLV-Nogo-B re-
duced VSMC proliferation.
(A) IDLV-Nogo-B blocked
VSMC proliferation, as as-
sessed with anMTT assay at 5
days post infection. *p < 0.001
vs. their LV-eGFP control and
uninfected. (B) Represen-
tativemicrographs (at anMOI
of 50). Scale bar, 100lm. (C)
IDLV-Nogo-B did not induce
VSMC apoptosis, as demon-
strated using a caspase-3/7
activity assay 5 days post-
transduction at an MOI of 50.
Table 1. Overview of Analyzed ICLV
and IDLV Insertion Sites in Human
Vascular Smooth Muscle Cells
Patient Vector MOI
Unique
mappable IS
Multiple
mappable IS
10 20 8
P1 IDLV 25 24 16
50 27 18
10 16 27
P2 IDLV 25 19 14
50 18 11
10 24 8
P3 IDLV 25 25 8
50 23 8
Total 196 118
10 1972 169
P1 ICLV 25 1475 163
50 1950 208
10 1756 179
P2 ICLV 25 1953 177
50 290 40
10 778 91
P3 ICLV 25 578 59
50 n.d n.d
Total 10752 1086
MOI, multiplicity of infection; IS, integration site; IDLV, integrase-
deficient lentiviral vectors; ICLV, integrase-competent lentiviral
vectors; n.d, no data.
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genome (Table 1). IS analyses on IDLV-transduced VSMCs
identified 196 uniquemappable and 118multiple mappable IS
sites, clearly verifying the reduced integration frequency of
IDLV-based vectors (Table 1). Strengthening the observation
that most integrated IDLV genomes result from a mechanism
inconsistent with residual integrase activity (see Matrai et al.,
2011), 28% of retrieved IDLV vector–cellular junctions con-
tained deletions in the LTR, whereas from all ICLV insertion
sites only 3% harbored deletions in the LTR. In addition,
mapping of IDLV IS showed a close-to-randomdistribution in
respect to integration within RefSeq genes (Fig. 4A). In con-
trast, ICLV IS showed the expected preference to integrate
into RefSeq genes, independent of the different MOI used.
Therefore, the sequences of the individual replicates were
combined for further analyses (Fig. 4A and B).
We further analyzed the propensity of ICLV IS to be lo-
cated in CIS. CIS are defined as chromosomal regions where
multiple IS sites in the host genome are nonrandomly en-
riched. The order of CIS is defined by the number of indi-
vidual IS located in a specific genomic window size (Abel
et al., 2011). We did not detect any CIS while analyzing the
IDLV IS; however, the analyses of the ICLV IS in patient
(P)1–P3 revealed that 15 to 19% (p < 0.0001) of total IS were
located in CIS of higher orders (> 6th order) (Fig. 4C).
Strikingly, IS in CIS were present in all three samples ana-
lyzed to a similar intensity, indicating that an intrinsic IS bias
may be responsible for this observed nonrandom distribu-
tion (Fig. 4C). A total of 708 RefSeq genes were associated
with these CIS, of which 24% are also listed as cancer genes
(www.cbio.mskcc.org). Notably, no CIS were detected in the
vicinity of EVI1, MDS1, CCND2, or LMO2, which have
previously been described as genes whose insertional acti-
vation cause severe side effects in gammaretroviral gene
therapy trials (Nowrouzi et al., 2011). Although ICLV vectors
have been shown to be intrinsically less prone to insertional
mutagenesis (Montini et al., 2006; Cartier et al., 2009; Modlich
et al., 2009; Montini et al., 2009; Bartholomae et al., 2011; Biffi
et al., 2011; Nowrouzi et al., 2011), this comparative analyses
FIG. 4. Distribution of ICLV and IDLV insertion sites in human vascular smooth muscle cells. (A) Frequency of ICLV and
IDLV integration inside RefSeq genes. (B) Distribution of insertion sites inside and 10 kb upstream of RefSeq genes nor-
malized to the expected random distribution of 5.000 computer-simulated random insertion sites. (C) ICLV insertion sites in
VSMCs show regional clustering in common insertion sites (CIS) in three independently analyzed patient samples to a similar
frequency. (D) Vector copy number (VCN) normalized to erythropoietin (EPO) gene at 14 days post-transduction. ICLV,
integrase-competent lentiviral vectors.
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shows that due to the reduced integration frequency, the
propensity for insertional induced deregulation of cellular
genes is most likely reduced with IDLV and that IDLV-
mediated gene transfer into primary human vascular cells
shows a substantially improved genotoxic safety profile. For
evaluating the minimal IDLV copy number required to
achieve effects mediated by this particular gene delivery
system in the context of vascular gene transfer, we performed
q-PCR on ICLV and IDLV transduced samples 14 days post
transduction (Fig. 4D). IDLV vector copy numbers (VCN)
were reduced compared to ICLV 14 days post transduction
(Fig. 4D). However, IDLV mediated efficient gene transfer in
VSMCs (Fig. 1) and attained similar phenotypic effects com-
pared to their integrating counterparts (Figs. 2 and 3).
Discussion
The main aim of this study was to construct and assess a
suitable candidate IDLV for potential application to vascular
gene therapy, and to assess the safety implications in the
context of integration events in primary human vascular
cells. For the first time, this study reported the important
feasibility of IDLVs for use in vascular cell gene transfer
studies, which provided efficient transgene expression in
VSMCs and led to effective phenotypic effects on VSMC
migration and proliferation in vitro, concomitantly associated
with very low integration frequencies. Our data supports the
use of IDLV in general and the potential of Nogo-B as a
candidate gene for therapeutic application to acute vascular
injury using this system. It has already been reported that
LVs have the potential to mediate gene transfer of transgenes
into primary vascular cells within a short time exposure
(minutes of exposure), which is required in this clinical set-
ting (Dishart et al., 2003; Cefai et al., 2005). IDLVs would be
highly advantageous in vascular gene therapy based on the
improved safety profile. Notably, our results here indicated
efficient transgene expression in VSMCs can be achieved by
IDLVs. However, IDLVs did not provide enhanced efficient
and long-term eGFP expression as well as their integrase-
competent counterparts in VSMCs. IDLVs expressed lower
transgene expression than their integrating counterparts,
which is in correlation with earlier studies (Bayer et al., 2008;
Matrai et al., 2011).
In addition, these findings corroborated with those of
previous studies in dividing cells, which reported that IDLV-
mediated transient transgene expression was due to epi-
somes lacking replication signals and thus diluting as a
consequence of cell division (Nightingale et al., 2006; Philippe
et al., 2006; Apolonia et al., 2007; Matrai et al., 2011). In the
vascular setting in vivo, this is worthy of further evaluation
since blockade in vascular phenotypes in the short-term post-
acute injury using adenoviruses have been shown to provide
long-term protection (George et al., 2011). Clearly, strategies
that slow or block VSMC proliferation in vivo would result in
sustained transgene expression in the vessel wall. In addi-
tion, VSMCs have relatively low rates of proliferation in a
disease state (Gordon et al., 1990), and during the acute
vascular injury response ( Westerband et al., 1997; Hilker
et al., 2002) with a proliferative index of approximately 1.34%
(Westerband et al., 1997). Therefore, it is suggested that the
IDLV-mediated episomal transgene would dilute slowly, but
persist for the duration required (George et al., 2006; White
et al., 2007). In addition, one can speculate that Nogo-B’s
effect on the inhibition of VSMC proliferation would also
assist with the longevity of transgene mediated by IDLV-
based episomal genomes.
Previous studies have shown IDLVs, especially the D64V
mutants, to have important implications relevant for gene
delivery into nondividing cells within different organs (eye,
muscle, central nervous system, and liver of rodents), by
retaining transduction efficiency of their wild-type integrase
versions with minimal host genome integration in vitro and
in vivo (Yanez-Munoz et al., 2006; Apolonia et al., 2007;
Rahim et al., 2009; Matrai et al., 2011). In relation to these
preclinical reports, results from this in vitro study implied
efficient gene transfer and transgene expression mediated
by IDLV-Nogo-B in human VSMCs, and as consequence
was as efficient in modulating phenotypic effects of VSMCs.
Therefore, the data reported herein denotes the use of IDLVs
as an alternative and promising gene transfer vector system.
However, the lack of ability to produce the high titres for
LVs (Matrai et al., 2010) required for in vivo vascular gene
transfer provides a substantial barrier and disadvantage for
this vector system to be used in further vasculature studies
in vivo at present.
We demonstrate that IS selection of ICLV in human
VSMCs follows typical lentiviral target site patterns; how-
ever, regional hotspots resulting in higher order CIS have
been detected. The propensity of ICLV insertions to be lo-
cated in such CIS is significantly higher than expected by
chance. Given that most genotoxic side effects in gene ther-
apy trials using gammaretroviral vectors have been triggered
by insertional activation of cellular genes located in close
proximity to gammaretroviral CIS, it has recently been sug-
gested that LV hotspots reflect a benign integration bias
rather than oncogenic selection (Biffi et al., 2011). We further
show that IDLV-based vectors integrate at very low fre-
quency and randomly in human VSMCs, and therefore re-
duce the risk of insertional mutagenesis. This finding is
consistent with a previous report (Matrai et al., 2011) and
further strengthened by q-PCR, where we observed no major
differences regarding VCN between IDLV (MOI of 50)
and ICLV (MOI of 25). However, with LAM-PCR, we re-
trieved much higher integrated vector copies supporting the
observed reduced integration frequency despite possible
competition of episomal persisting IDLV (Fig. 4A, B, and D;
Table 1).
We conclude that IDLV provide differences in VCN
compared to ICLV but still attain similar phenotypic effects.
In relation to these IS results, active transcriptional units of
nondividing cells possess fewer LV-mediated integration
frequencies, with a similar association to a random distri-
bution of integration, unlike that of rapidly dividing cells.
Moreover, LV-mediated integration sites were most com-
monly found in nonexpressed genes of postmitotic cells
(Bartholomae et al., 2011). This could have possible impli-
cations in LV-transduced VSMCs (Gordon et al., 1990;
Westerband et al., 1997; Hilker et al., 2002).
We note that IS patterns obtained from dividing VSMCs
in vitromay not reflect the pattern of integration mediated by
ICLV in VSMCs in vivo as described in other tissues previ-
ously (Bartholomae et al., 2011). In a recent study, IDLV-
mediated gene delivery in hepatocytes gave rise to random
integrations without obvious skewing toward gene-coding
1254 CHICK ET AL.
regions (Matrai et al., 2011). Therefore, it is possible that
ICLVs and most importantly IDLVs could give rise to a
lesser likelihood of genotoxicity in VSMCs (Bartholomae
et al., 2011; Matrai et al., 2011).
Taken together, this study addresses the potential of
IDLVs for future use in vascular cell gene delivery studies
with associated low-integration frequencies, with justifica-
tion to take forward this new candidate IDLV-Nogo-B into
in vivo models of acute vascular injury.
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